whirlpool Venlafaxine | Velaxin tablets 75 mg 28 pcs.
Special Price
$32.98
Regular Price
$42.00
In stock
SKU
BID463688
Latin name
Velaxin
Velaxin
Latin name
Velaxin
Packing
28 pcs
Pharmacological action
Velaxin has an antidepressant effect.
Indications
Depression (with or without symptoms of anxiety) both on an outpatient basis and in a hospital.
Prevention of relapse of depression (with a positive therapeutic effect).
Contraindications
Hypersensitivity, concomitant use of MAO inhibitors, severe renal impairment (glomerular filtration rate 18 s), age up to 18 years (safety and effectiveness for this age group not proven), pregnancy or suspected pregnancy, lactation period (there are insufficient data research).
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation (breastfeeding). If venlafaxine was used immediately before birth or shortly before birth, it is necessary to take into account the possibility of developing a withdrawal syndrome in a newborn.
Dosage and administration of
Velaxin is taken orally during meals. The recommended starting dose is 75 mg daily.
Side effects
General symptoms: weakness, fatigue.
From the gastrointestinal tract: decreased appetite, constipation, nausea, vomiting, dry mouth, rarely hepatitis.
From the side of metabolism: increase in serum cholesterol, decrease in body weight, sometimes - change in the results of laboratory tests of liver function, hyponatremia, syndrome of insufficient secretion of antidiuretic hormone.
From the cardiovascular system: arterial hypertension, hyperemia of the skin, postural hypotension, tachycardia.
From the side of the central nervous system: unusual dreams, dizziness, insomnia, increased irritability, paresthesia, stupor, increased muscle tone, tremors, yawning sometimes - apathy, hallucinations, muscle cramps, serotonin syndrome, rarely - epileptic seizures, manic reactions, as well as symptoms, resembling malignant antipsychotic syndrome.
From the genitourinary system: disturbances in ejaculation, erection, anorgasmia, dysuric disorders (mainly difficulties at the beginning of urination), sometimes - decreased libido, menorrhagia, urinary retention.
From the sensory organs: accommodation disorders, mydriasis, visual impairment infrequently - a violation of taste sensations.
From the skin: sweating sometimes - photosensitivity reactions rarely - erythema multiforme, Stevens-Johnson syndrome.
From the hemopoietic system: sometimes - hemorrhages in the skin (ecchymosis) and mucous membranes, thrombocytopenia rarely - prolongation of bleeding time.
Drug Interaction
Incompatible with MAO inhibitors.
Reduces indinavir AUC by 28% and Cmax by 36% (clinical significance is unknown).
Increases the anticoagulant effect of warfarin.
Increases the effect of ethanol on psychomotor responses.
Oral administration reduces the total clearance of haloperidol by 42%, increases its AUC by 70% and Cmax by 88%.
Cimetidine suppresses first-pass metabolism of venlafaxine and has no effect on the pharmacokinetics of O-desmethylvenlafaxine. Most patients expect only a slight increase in the total pharmacological activity of venlafaxine and O-desmethylvenlafaxine (more pronounced in elderly patients and with impaired liver function).
Has no effect on the pharmacokinetics of imipramine and 2-OH-imipramine, however, the AUC, Cmax and Cmin rates of desipramine increased by 35% and the AUC of 2-OH-desipramine 2.5-4.5 times.
Increases risperidone AUC by 32%, but has no significant effect on the overall pharmacokinetic profile of the active components - risperidone plus 9-hydroxyrisperidone (the clinical significance of the identified phenomenon is unknown).
Does not interact with lithium preparations also with drugs metabolised by CYP3A4, CYP1A2 and CYP2C9 (including alprazolam, caffeine, carbamazepine, diazepam).
Does not affect the plasma concentration of drugs that have a high degree of protein binding.
Overdose
Symptoms (often associated with ethanol intake): dizziness, decreased blood pressure, ECG changes (QT lengthening, blockage of the GIS bundle, QRS extension), sinus and ventricular tachycardia ), convulsions and death.
Treatment - Symptomatic control of ECG and vital organs at risk of vomiting aspiration is not recommended to wash (if overdose has occurred recently, or symptoms of overdose remain) activated charcoal. The efficacy of using forced diuresis, dialysis, hemoperfusion and blood transfusions has not been proven specific antidotes are unknown.
Storage conditions
Store the drug in a dry, dark place at a temperature of no higher than 25C.
The Expiration of
is 3 years.
pharmacy terms
pharmacy prescription
dosage form
dosage form
tablets
Velaxin
Packing
28 pcs
Pharmacological action
Velaxin has an antidepressant effect.
Indications
Depression (with or without symptoms of anxiety) both on an outpatient basis and in a hospital.
Prevention of relapse of depression (with a positive therapeutic effect).
Contraindications
Hypersensitivity, concomitant use of MAO inhibitors, severe renal impairment (glomerular filtration rate 18 s), age up to 18 years (safety and effectiveness for this age group not proven), pregnancy or suspected pregnancy, lactation period (there are insufficient data research).
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation (breastfeeding). If venlafaxine was used immediately before birth or shortly before birth, it is necessary to take into account the possibility of developing a withdrawal syndrome in a newborn.
Dosage and administration of
Velaxin is taken orally during meals. The recommended starting dose is 75 mg daily.
Side effects
General symptoms: weakness, fatigue.
From the gastrointestinal tract: decreased appetite, constipation, nausea, vomiting, dry mouth, rarely hepatitis.
From the side of metabolism: increase in serum cholesterol, decrease in body weight, sometimes - change in the results of laboratory tests of liver function, hyponatremia, syndrome of insufficient secretion of antidiuretic hormone.
From the cardiovascular system: arterial hypertension, hyperemia of the skin, postural hypotension, tachycardia.
From the side of the central nervous system: unusual dreams, dizziness, insomnia, increased irritability, paresthesia, stupor, increased muscle tone, tremors, yawning sometimes - apathy, hallucinations, muscle cramps, serotonin syndrome, rarely - epileptic seizures, manic reactions, as well as symptoms, resembling malignant antipsychotic syndrome.
From the genitourinary system: disturbances in ejaculation, erection, anorgasmia, dysuric disorders (mainly difficulties at the beginning of urination), sometimes - decreased libido, menorrhagia, urinary retention.
From the sensory organs: accommodation disorders, mydriasis, visual impairment infrequently - a violation of taste sensations.
From the skin: sweating sometimes - photosensitivity reactions rarely - erythema multiforme, Stevens-Johnson syndrome.
From the hemopoietic system: sometimes - hemorrhages in the skin (ecchymosis) and mucous membranes, thrombocytopenia rarely - prolongation of bleeding time.
Drug Interaction
Incompatible with MAO inhibitors.
Reduces indinavir AUC by 28% and Cmax by 36% (clinical significance is unknown).
Increases the anticoagulant effect of warfarin.
Increases the effect of ethanol on psychomotor responses.
Oral administration reduces the total clearance of haloperidol by 42%, increases its AUC by 70% and Cmax by 88%.
Cimetidine suppresses first-pass metabolism of venlafaxine and has no effect on the pharmacokinetics of O-desmethylvenlafaxine. Most patients expect only a slight increase in the total pharmacological activity of venlafaxine and O-desmethylvenlafaxine (more pronounced in elderly patients and with impaired liver function).
Has no effect on the pharmacokinetics of imipramine and 2-OH-imipramine, however, the AUC, Cmax and Cmin rates of desipramine increased by 35% and the AUC of 2-OH-desipramine 2.5-4.5 times.
Increases risperidone AUC by 32%, but has no significant effect on the overall pharmacokinetic profile of the active components - risperidone plus 9-hydroxyrisperidone (the clinical significance of the identified phenomenon is unknown).
Does not interact with lithium preparations also with drugs metabolised by CYP3A4, CYP1A2 and CYP2C9 (including alprazolam, caffeine, carbamazepine, diazepam).
Does not affect the plasma concentration of drugs that have a high degree of protein binding.
Overdose
Symptoms (often associated with ethanol intake): dizziness, decreased blood pressure, ECG changes (QT lengthening, blockage of the GIS bundle, QRS extension), sinus and ventricular tachycardia ), convulsions and death.
Treatment - Symptomatic control of ECG and vital organs at risk of vomiting aspiration is not recommended to wash (if overdose has occurred recently, or symptoms of overdose remain) activated charcoal. The efficacy of using forced diuresis, dialysis, hemoperfusion and blood transfusions has not been proven specific antidotes are unknown.
Storage conditions
Store the drug in a dry, dark place at a temperature of no higher than 25C.
The Expiration of
is 3 years.
pharmacy terms
pharmacy prescription
dosage form
dosage form
tablets
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review